Dr. Reddy’s Laboratories (NYSE:RDY) Issues Earnings Results, Beats Expectations By $0.01 EPS

Dr. Reddy’s Laboratories (NYSE:RDY) posted its earnings results on Thursday. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01, Zacks reports. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%.

Dr. Reddy’s Laboratories Stock Down 5.1 %

Shares of Dr. Reddy’s Laboratories stock traded down $0.78 on Thursday, reaching $14.32. The stock had a trading volume of 674,242 shares, compared to its average volume of 2,212,194. The company has a 50 day moving average price of $14.87 and a 200 day moving average price of $15.54. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories has a 1 year low of $13.61 and a 1 year high of $16.89. The stock has a market capitalization of $11.95 billion, a P/E ratio of 22.87 and a beta of 0.51.

Analyst Ratings Changes

A number of research firms have commented on RDY. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. Barclays cut their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.